A review of adherence to drug therapy in patients with overactive bladder

被引：112

作者：

Basra, Ramandeep K. ^{[1
]}

Wagg, Adrian ^{[2
]}

Chapple, Christopher ^{[3
]}

Cardozo, Linda ^{[4
]}

Castro-Diaz, David ^{[6
]}

Pons, Montserrat Espuna ^{[7
]}

Kirby, Mike ^{[5
]}

Milsom, Ian ^{[8
]}

Vierhout, Mark ^{[9
]}

Van Kerrebroeck, Philip ^{[10
]}

Kelleher, Con ^{[1
]}

机构：

[1] Guys St Thomas NHS Fdn Trust, Sheffield, S Yorkshire, England

[2] Univ Coll London, Sheffield, S Yorkshire, England

[3] Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England

[4] Kings Coll Hosp London, London, England

[5] Univ Hertfordshire, Ctr Res Primary & Community Care, Hatfield AL10 9AB, Herts, England

[6] Univ Canarias, Tenerife, Spain

[7] Univ Barcelona, Barcelona, Spain

[8] Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden

[9] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands

[10] Univ Hosp Maastricht, Maastricht, Netherlands

来源：

BJU INTERNATIONAL | 2008年 / 102卷 / 07期

关键词：

adherence; overactive bladder; pharmacotherapy;

D O I：

10.1111/j.1464-410X.2008.07769.x

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Drug therapy for overactive bladder (DAB) is associated with improvements in symptoms and quality of life, but the short- and long-term adherence and persistence is suboptimal. In this review we outline methods of measuring, and factors affecting, adherence to pharmacatherapy in patients with CAB. Clinical practice suggests that adherence rates reported in clinical trials art much greater than in real practice. Factors affecting adherence include psychological and social variables that might alter patients' perception of the benefits of taking medication, and the effect of comorbidity and polypharmacy. Whilst there is some evidence that lack of efficacy and side-effects are contributory, these additional factors are also important.

引用

页码：774 / 779

页数：6

共 50 条

[1] A Review of Adherence to Drug Therapy in Patients With Overactive Bladder Editorial Comment
Wein, Alan J.
JOURNAL OF UROLOGY, 2009, 182 (03): : 1084 - 1084
[2] A LONG TERM COMPARISON OF ADHERENCE OF DRUG THERAPY IN 1,917 PATIENTS WITH OVERACTIVE BLADDER
Kajikawa, Keishi
Kanao, Kent
Morinaga, Shingo
Muramatsu, Hiroyuki
Saiki, Hiroshi
Kobayashi, Ikuo
Kato, Yoshiharu
Watanabe, Masahito
Nakamura, Kogenta
Sumitomo, Makoto
JOURNAL OF UROLOGY, 2017, 197 (04): : E509 - E509
[3] Drug therapy for an overactive bladder
Thiagamoorthy, Ganesh
Cardozo, Linda
Srikrishna, Sushma
WOMENS HEALTH, 2015, 11 (04) : 445 - 448
[4] Drug therapy for overactive bladder
Izett, M.
Zacche, M.
Giarenis, I.
Robinson, D.
Cardozo, L.
MINERVA GINECOLOGICA, 2015, 67 (06): : 557 - 574
[5] Predictors of compliance with drug therapy in patients with overactive bladder
Basra, R.
Cortes, E.
Basra, H.
Khullar, V
Kelleher, C.
INTERNATIONAL UROGYNECOLOGY JOURNAL, 2008, 19 : S39 - S40
[6] Drug persistence and adherence in the treatment of overactive bladder
Radomski, Sidney B.
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2015, 9 (9-10): : 351 - 352
[7] Barriers and facilitators to overactive bladder therapy adherence
Enemchukwu, Ekene A.
Subak, Leslee L.
Markland, Alayne
NEUROUROLOGY AND URODYNAMICS, 2022, 41 (08) : 1983 - 1992
[8] Drug therapy - Management of overactive bladder
Ouslander, JG
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (08): : 786 - 799
[9] Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature
Sexton, C. C.
Notte, S. M.
Maroulis, C.
Dmochowski, R. R.
Cardozo, L.
Subramanian, D.
Coyne, K. S.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (05) : 567 - 585
[10] Mirabegron in overactive bladder patients: efficacy review and update on drug safety
Warren, Katherine
Burden, Helena
Abrams, Paul
THERAPEUTIC ADVANCES IN DRUG SAFETY, 2016, 7 (05) : 204 - 216

← 1 2 3 4 5 →